A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 23% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: bevacizumabpatients mustglioblastomagliomaradiation
  Phrases that lowered it: participantsparticipantpressureblood14 days
• Sponsor's past termination rate: 20.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 211 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 33.5% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 77 (lowers risk) · Sponsor's track record
• Keywords listed: 5 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Drug's FAERS reports marked serious: 96.4% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 34268 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma NCT01149850 · started 2010 · scored riskier than 62% of active trials completed
• Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme NCT00883298 · started 2009 · scored riskier than 70% of active trials completed
• Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma NCT00720356 · started 2009 · scored riskier than 99% of active trials completed
• Amgen 386 for Recurrent Glioblastoma NCT01290263 · started 2010 · scored riskier than 79% of active trials completed
• Bevacizumab Beyond Progression (BBP) NCT01740258 · started 2013 · scored riskier than 89% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.